VANCOUVER, Feb. 14, 2020 /CNW/ - Sirona Biochem Corp.
(TSX-V: SBM) (FSE: ZSB) (US-OTC:SRBCF) (the "Company") announces
that it has changed its auditors from MNP LLP (the "Former
Auditor") to DeVisser Gray LLP (the "Successor Auditor") effective
January 27, 2020 and the board of
directors of the Company appointed the Successor Auditor as the
Company's auditor effective January 27,
2020 until the next Annual General Meeting of the Company.
There were no reservations in the Former Auditor's audit reports
for the relevant period, being the financial years ended
October 31, 2018 and October 31, 2017 and any period subsequent to the
most recently completed financial year for which an audit report
was issued and preceding the resignation of the Former Auditor. In
accordance with National Instrument 51-102 – Continuous Disclosure
Obligations ("NI 51-102"), the Company has filed a Change of
Auditor Notice (the "Notice") on SEDAR together with letters from
both the Former Auditor and Successor Auditor, with each lettering
confirming agreement with the statements contained in the Notice,
as applicable. There were no reportable events as defined in
NI 51-102 between the Former Auditor and the Company.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery
company with a proprietary platform technology. Sirona's subsidiary
lab, TFChem, specializes in stabilizing carbohydrate molecules with
the goal of improving efficacy and safety. New compounds are
patented for maximum revenue potential.
Sirona's compounds are licensed to leading companies around the
world in return for licensing fees, milestone fees and ongoing
royalty payments.
For more information, please visit www.sironabiochem.com
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of release of the relevant information, unless
explicitly stated otherwise. Actual results, performance or
achievement could differ materially from those expressed in, or
implied by, Sirona Biochem's forward-looking statements due to the
risks and uncertainties inherent in Sirona Biochem's business
including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in
development, testing, obtaining regulatory approval, producing and
marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from
other pharmaceutical or biotechnology companies; and its ability to
obtain additional financing to support its operations. Sirona
Biochem does not assume any obligation to update any
forward-looking statements except as required by law.
SOURCE Sirona Biochem Corp.